The FARAPULSE FARA-Freedom Trial

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 180 participants.

Also called NCT05072964

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 180 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05072964
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Belgium, Czechia, Denmark, Germany, Netherlands, Switzerland (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05072964. Allocation not applicable; no masking; primary purpose treatment. Start 2021-12-21 (actual); primary completion 2023-10-12 (actual). Results posted on 2024-10-17.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The FARAPULSE FARA-Freedom Trial
Acronym
FARA-Freedom
Condition
Paroxysmal Atrial Fibrillation
Intervention (Device)
FARAPULSE Pulsed Field Ablation System
Lead sponsor
Boston Scientific Corporation (class: industry)

Record details

Record id
cardio:ct-nct05072964
Content hash
7b4e8797ba83b50e2f273e2de911bf8b57ff982f81d66578c8b31437534bb8a8